


IN THE CLAIMS:

1. (Currently amended) A compound comprising formula I



wherein

R^1, R^1, R^2 each, independently of one another, are selected from the group consisting of Hal, A, OH, OA, SA, SO_2H , SO_2A , SO_3H , SO_3A , CN, NO_2 , NH_2 , NHA, NAA' , $NHCOA$, CHO, $C(=O)A$, COOH, COOA, $CONH_2$, CONHA and $CONAA'$,

L is selected from the group consisting of CH_2 , ~~CH_2CH_2~~ , O, and S, ~~SO_2~~ , SO_2NH , NA, ~~$C=O$~~ or $CHOH$,

E, G, M,

Q and U each, independently of one another, are selected from the group consisting of a C atom and ~~or~~ an N atom, with the proviso that at least one of E, G, M, Q or U is an N atom

A, A', independently of one another, are selected from the group consisting of unsubstituted or substituted alkyl having 1-10 C atoms, unsubstituted or substituted cycloalkyl having 3-10 C atoms, unsubstituted or substituted alkoxyalkyl having 2-12 C atoms, unsubstituted or substituted aryl having 6-14 C atoms,

unsubstituted or substituted arylalkyl having 7-15 C atoms,
~~unsubstituted or substituted, saturated, unsaturated or aromatic~~
~~heterocyclyl having 2-7 C atoms and 1-3 hetero atoms selected~~
~~from the group consisting of N, O and S, or unsubstituted or~~
~~substituted, saturated, unsaturated or aromatic heterocyclylalkyl~~
~~having 3-10 C atoms and 1-3 hetero atoms selected from~~
~~consisting of N, O and S,~~

Hal is selected from the group consisting of F, Cl, Br and ~~or~~ I, and
m, p, q each, independently of one another, are 0, 1, 2, 3 or 4,

~~and pharmaceutically usable derivatives; or physiologically acceptable~~
~~salts, solvates and or~~ stereoisomers thereof, including mixtures thereof in
all ratios.

2. (Currently amended) The compound according to Claim 1, wherein
R¹, independently of one another, is selected from the group
consisting of A, Hal, CN, COOH, COOA, SO₂A, C(=O)A, NH₂,
NHA and NO₂, and
m is 1, 2 or 3,
~~and pharmaceutically usable derivatives; or physiologically acceptable~~
~~salts, solvates and or~~ stereoisomers thereof, including mixtures thereof in
all ratios.
3. (Currently amended) The compound according to Claim 1 wherein
R¹, independently of one another, is selected from the group
consisting of methyl, ethyl, CF₃, OCF₃, F, Cl, Br, CN, COOH,

COOCH₃, COOCH₂CH₃, SO₂CH₃, NH₂, NHCH₃, NHCH₂CH₃,
NO₂, and thiophen-2-ylcarbonyl, and

m is 1, 2 or 3,

~~and pharmaceutically usable derivatives;~~ or physiologically acceptable salts, solvates ~~and or~~ stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently amended) The compound according to claim 1 wherein
R¹ is Hal or A,
p is 0 or 1,
~~and pharmaceutically usable derivatives;~~ or physiologically acceptable salts, solvates ~~and or~~ stereoisomers thereof, including mixtures thereof in all ratios.
5. (Cancelled)
6. (Currently amended) The compound according to claim 1 wherein
R² is selected from the group consisting of A, COOA, CONHA and
or CONH₂, and
q is 0, 1 or 2,
~~and pharmaceutically usable derivatives;~~ or physiologically acceptable salts, solvates ~~and or~~ stereoisomers thereof, including mixtures thereof in all ratios.
7. (Currently amended) The compound according to claim 1 wherein

R^1 , independently of one another, is selected from the group consisting of Hal, alkyl, CN, COOH, COOalkyl, SO₂alkyl, NH₂, NHalkyl, C(=O)alkyl, C(=O)heterocyclyl and NO₂,

m is 1, 2 or 3

$R^{1'}$ is Hal or A

p is 0 or 1,


L is selected from the group consisting of O, S and or CH₂,

R^2 is selected from the group consisting of A, COOalkyl, CONHalkyl and CONH₂, and


q is 0, 1 or 2,

~~and pharmaceutically usable derivatives, or physiologically acceptable salts, solvates and or~~ stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently amended) The compound according to claim 1 wherein the group



in formula I is selected from the group consisting of



wherein L, R² and q have the meanings indicated in claim 1,
~~and pharmaceutically usable derivatives, or physiologically acceptable~~
~~salts, solvates and or~~ stereoisomers thereof, including mixtures thereof in
 all ratios.

9. (Currently amended) The compound according to claim 1, selected from the group consisting of
 - (5-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - [4-(pyridin-4-yloxy)phenyl](6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
 - (6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (5-chloro-4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 - (5,6-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;

(5-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(5,6-dichloro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(5,6-dichloro-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(5-chloro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(5-chloro-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4,5-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(5-chloro-6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(5-chloro-6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4,6-bistrifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
(4,6-bistrifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
[4-(pyridin-3-yloxy)phenyl](6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
(6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4,5-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(5-chloro-4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;

(5,6-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
(4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(2,6-dimethyl-pyrimidin-4-yloxy)phenyl]amine;

N-methyl-4-[4-(bromotrifluoromethyl-1H-benzimidazol-2-ylamino)phenoxy]pyridine-2-carboxamide;

2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carbonitrile;
[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;

(4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(2,6-dimethyl-pyrimidin-4-yloxy)phenyl]amine;

[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;

(6-nitro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
methyl 2-[4-(pyridin-4-yloxy)-

phenylamino]-3H-benzimidazole-5-carboxylate;

2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carboxylic acid;

methyl

7-methanesulfonyl-2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carboxylate;

(4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;

[4-(2,6-dimethylpyrimidin-4-yloxy)phenyl](4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;


[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;

N-methyl-4-{4-[6-(1-thiophen-2-ylmethanoyl)-1H-benzimidazol-2-yl]-


amino]phenoxy}pyridine-2-carboxamide; and
 N^2 -[4-(pyridin-4-yloxy)phenyl]-3H-benzimidazole-2,5-diamine;
 and pharmaceutically usable derivatives, or physiologically acceptable salts, solvates and or stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently amended) A process for the preparation of a compound compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, or physiologically acceptable salts, solvates and or stereoisomers thereof, including mixtures thereof in all ratios, comprising reacting

a compound of the formula II



wherein R^1 and m have the meanings indicated in Claim 1,
 with a compound of the formula III



wherein R^1 , L, E, G, M, Q, U, R^2 and q have the meanings indicated in Claim 1,

and optionally converting the compound of formula I into a salt.

11. (Currently amended) A pharmaceutical composition comprising at least one compound according to claim 1 ~~and pharmaceutically usable derivatives, or physiologically acceptable salts, solvates and or~~ stereoisomers thereof, including mixtures thereof in all ratios, ~~and or~~ optionally excipients or ~~and/or~~ adjuvants.
12. (Previously presented) A method of treatment of diseases comprising inhibiting, regulating or modulating kinase signal transduction comprising administering to a patient in need thereof, a pharmaceutical composition according to claim 11.
13. (Currently amended) The method according to Claim 12, wherein said kinases are ~~selected from the group consisting of tyrosine kinases and Raf kinases.~~
14. (Previously presented) The method according to Claim 13, wherein said tyrosine kinases are TIE-2.
- 15.-16. (Cancelled)
17. (Previously presented) The method according to Claim 12 wherein said disease comprises a solid tumour.
18. (Previously presented) The method according to Claim 17, wherein said solid tumour originates from the group consisting of brain tumour,

tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour and lung tumour.


19. (Previously presented) The method according to Claim 17, wherein said solid tumour originates from the group consisting of monocytic leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.
20. (Previously presented) The method according to Claim 12 wherein angiogenesis is implicated in said disease.
21. (Previously presented) The method according to Claim 20, wherein said disease is an ocular disease.
22. (Previously presented) The method according to Claim 12 wherein said disease is selected from the group consisting of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and inflammatory diseases.
23. (Previously presented) The method according to Claim 22, wherein said inflammatory disease originates from the group consisting of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction.
24. (Previously presented) The method according to Claim 12 wherein said disease involves bone pathologies, wherein said bone pathology originates from the group consisting of osteosarcoma, osteoarthritis and rickets.
25. (Previously presented) The pharmaceutical composition according to

claim 11 comprising at least one additional active ingredient.

26. (Previously presented) A kit comprising separate packs of
- (a) an effective amount of a compound according to Claim 1 or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
 - and
 - (b) an effective amount of ad additional active ingredient.
27. (Previously presented) The method according to claim 12 wherein said pharmaceutical composition is administered in combination with a compound from the group consisting of 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
28. (Previously presented) The method according to claim 12 wherein said pharmaceutical composition is administered in combination with radiotherapy and a compound from the group consisting of 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

29. (Previously presented) The method according to claim 12 wherein said pharmaceutical composition is administered in combination with a growth-factor receptor inhibitor.
- 30.-31. (Cancelled)
32. (Previously presented) The method according to Claim 12 wherein said diseases are selected from the group consisting of hyperproliferative and non-hyperproliferative diseases.
33. (Previously presented) The method according to claim 12 wherein said disease is cancerous.
34. (Previously presented) The method according to claim 12 wherein said disease is non-cancerous.
35. (Previously presented) The method according to claim 34 wherein said non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.
36. (Previously presented) The method according to claim 33 wherein said cancerous diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

37. (New) A compound comprising formula I



wherein

R^1, R^1 each, independently of one another, are selected from the group consisting of Hal, A, OH, OA, SA, SO_2H , SO_2A , SO_3H , SO_3A , CN, NO_2 , NH_2 , NHA, NAA' , $NHCOA$, CHO, $C(=O)A$, COOH, COOA, $CONH_2$, CONHA and $CONAA'$, wherein A, A' independently of one another, are selected from the group consisting of unsubstituted or substituted alkyl having 1-10 C atoms, unsubstituted or substituted cycloalkyl having 3-10 C atoms, unsubstituted or substituted alkoxyalkyl having 2-12 C atoms, unsubstituted or substituted aryl having 6-14 C atoms, unsubstituted or substituted arylalkyl having 7-15 C atoms,

R^2 is selected from the group consisting of Hal, A, OH, OA, SA, SO_2H , SO_2A , SO_3H , SO_3A , CN, NO_2 , NH_2 , NHA, NAA' , $NHCOA$, CHO, $C(=O)A$, COOH, COOA, $CONH_2$, CONHA and $CONAA'$, wherein A, A' independently of one another, are selected from the group consisting of unsubstituted or substituted alkyl having 1-10 C atoms, unsubstituted or substituted cycloalkyl having 3-10 C atoms, unsubstituted or substituted alkoxyalkyl having 2-12 C atoms, unsubstituted or substituted aryl having 6-14 C atoms, unsubstituted or substituted arylalkyl

having 7-15 C atoms, unsubstituted or substituted, saturated, unsaturated or aromatic heterocyclyl having 2-7 C atoms and 1-3 hetero atoms selected from the group consisting of N, O and S, or unsubstituted or substituted, saturated, unsaturated or aromatic heterocyclalkyl having 3-10 C atoms and 1-3 hetero atoms selected from consisting of N, O and S,

L is selected from the group consisting of CH₂, O, and S,

E, G, M,

Q and U each, independently of one another, are selected from the group consisting of a C atom and an N atom, with the proviso that at least one of E, G, M, Q or U is an N atom,

Hal is selected from the group consisting of F, Cl, Br and I, and

m, p, q each, independently of one another, are 0, 1, 2, 3 or 4,

or physiologically acceptable salts, solvates or stereoisomers thereof, including mixtures thereof in all ratios.